Advertisement

Topics

Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia

19:00 EDT 19 Jun 2017 | Net Resources International

Synlogic has begun dosing healthy volunteers in its Phase I clinical trial of SYNB1020 for the treatment of hyperammonemia associated with diseases such as urea cycle disorders (UCD) and hepatic encephalopathy (HE).

Original Article: Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia

NEXT ARTICLE

More From BioPortfolio on "Synlogic begins dosing in Phase I trial of SYNB1020 to treat hyperammonemia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...